These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 33443240)

  • 21. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis.
    Savard C; Tartaglione EV; Kuver R; Haigh WG; Farrell GC; Subramanian S; Chait A; Yeh MM; Quinn LS; Ioannou GN
    Hepatology; 2013 Jan; 57(1):81-92. PubMed ID: 22508243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic steatosis in obese Chinese children.
    Chan DF; Li AM; Chu WC; Chan MH; Wong EM; Liu EK; Chan IH; Yin J; Lam CW; Fok TF; Nelson EA
    Int J Obes Relat Metab Disord; 2004 Oct; 28(10):1257-63. PubMed ID: 15278103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Novel Nutraceuticals Mixture Improves Liver Steatosis by Preventing Oxidative Stress and Mitochondrial Dysfunction in a NAFLD Model.
    Sangineto M; Bukke VN; Bellanti F; Tamborra R; Moola A; Duda L; Villani R; Romano AD; Serviddio G
    Nutrients; 2021 Feb; 13(2):. PubMed ID: 33671262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease.
    Ryan MC; Itsiopoulos C; Thodis T; Ward G; Trost N; Hofferberth S; O'Dea K; Desmond PV; Johnson NA; Wilson AM
    J Hepatol; 2013 Jul; 59(1):138-43. PubMed ID: 23485520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH).
    Wu J; Zhang R; Shen F; Yang R; Zhou D; Cao H; Chen G; Pan Q; Fan J
    Med Sci Monit; 2018 Oct; 24():6946-6967. PubMed ID: 30270343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with ultrasound diagnosis of hepatic steatosis are at high metabolic risk.
    Kälsch J; Keskin H; Schütte A; Baars T; Baba HA; Bechmann LP; Canbay A; Sowa JP
    Z Gastroenterol; 2016 Dec; 54(12):1312-1319. PubMed ID: 27936481
    [No Abstract]   [Full Text] [Related]  

  • 28. The feasibility of T2 mapping in the assessment of hepatic steatosis, inflammation, and fibrosis in patients with non-alcoholic fatty liver disease: a preliminary study.
    Idilman IS; Celik A; Savas B; Idilman R; Karcaaltincaba M
    Clin Radiol; 2021 Sep; 76(9):709.e13-709.e18. PubMed ID: 34266657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study.
    Sorrentino G; Crispino P; Coppola D; De Stefano G
    Drugs R D; 2015 Mar; 15(1):21-5. PubMed ID: 25732561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients.
    Lee YH; Kim KJ; Yoo ME; Kim G; Yoon HJ; Jo K; Youn JC; Yun M; Park JY; Shim CY; Lee BW; Kang SM; Ha JW; Cha BS; Kang ES
    J Hepatol; 2018 Apr; 68(4):764-772. PubMed ID: 29175242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease.
    Yalamanchili K; Saadeh S; Klintmalm GB; Jennings LW; Davis GL
    Liver Transpl; 2010 Apr; 16(4):431-9. PubMed ID: 20373454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.
    Permutt Z; Le TA; Peterson MR; Seki E; Brenner DA; Sirlin C; Loomba R
    Aliment Pharmacol Ther; 2012 Jul; 36(1):22-9. PubMed ID: 22554256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts.
    Koh YC; Lin YC; Lee PS; Lu TJ; Lin KY; Pan MH
    Food Funct; 2020 Sep; 11(9):7545-7560. PubMed ID: 32815965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography.
    Chen J; Talwalkar JA; Yin M; Glaser KJ; Sanderson SO; Ehman RL
    Radiology; 2011 Jun; 259(3):749-56. PubMed ID: 21460032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease.
    Vilar Gomez E; Rodriguez De Miranda A; Gra Oramas B; Arus Soler E; Llanio Navarro R; Calzadilla Bertot L; Yasells Garcia A; Del Rosario Abreu Vazquez M
    Aliment Pharmacol Ther; 2009 Nov; 30(10):999-1009. PubMed ID: 19691668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemical shift magnetic resonance imaging is helpful in detecting hepatic steatosis but not fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).
    Kalra N; Duseja A; Das A; Dhiman RK; Virmani V; Chawla Y; Singh P; Khandelwal N
    Ann Hepatol; 2009; 8(1):21-5. PubMed ID: 19221529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dietary anthocyanins as nutritional therapy for nonalcoholic fatty liver disease.
    Valenti L; Riso P; Mazzocchi A; Porrini M; Fargion S; Agostoni C
    Oxid Med Cell Longev; 2013; 2013():145421. PubMed ID: 24282628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis.
    Xu G; Wang YM; Ying MM; Chen SD; Li ZR; Ma HL; Zheng MH; Wu J; Ding C
    Clin Mol Hepatol; 2021 Apr; 27(2):329-345. PubMed ID: 33465844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease.
    Patel NS; Peterson MR; Brenner DA; Heba E; Sirlin C; Loomba R
    Aliment Pharmacol Ther; 2013 Mar; 37(6):630-9. PubMed ID: 23383649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.